Burkitt lymphoma (Cancer)
Information
- Disease name
- Burkitt lymphoma
- Disease ID
- DOID:8584
- Description
- "A mature B-cell neoplasm of B-cells found in the germinal center." [url:http\://en.wikipedia.org/wiki/Burkitt%27s_lymphoma, url:http\://www.cancer.gov/dictionary?CdrID=45203]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02996773 | Active, not recruiting | Phase 1 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | November 29, 2016 | August 25, 2025 |
| NCT05693519 | Active, not recruiting | GastroIntestinal Cancer in Children and Adolescents | December 22, 2022 | June 22, 2023 | |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT01793233 | Active, not recruiting | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | June 17, 2013 | December 31, 2024 | |
| NCT02362035 | Active, not recruiting | Phase 1/Phase 2 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | February 20, 2015 | April 1, 2026 |
| NCT04450069 | Active, not recruiting | Phase 1 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | August 14, 2020 | June 2024 |
| NCT02443831 | Active, not recruiting | Phase 1 | CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies | April 2016 | December 31, 2036 |
| NCT04191187 | Active, not recruiting | Phase 2 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | December 6, 2019 | February 2025 |
| NCT03674411 | Active, not recruiting | Phase 2 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | January 2, 2019 | June 28, 2024 |
| NCT00849147 | Completed | Phase 2 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | October 2008 | November 2013 |
| NCT00864227 | Completed | Phase 2 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | December 2008 | November 2013 |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01092182 | Completed | Phase 2 | Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma | March 25, 2010 | February 16, 2023 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01109069 | Completed | Phase 2 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | June 2010 | April 26, 2019 |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01184885 | Completed | Early Phase 1 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | July 2010 | April 2013 |
| NCT01290120 | Completed | Phase 2 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | November 2002 | June 2014 |
| NCT01363128 | Completed | Phase 2 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | July 12, 2011 | April 8, 2020 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01786096 | Completed | Phase 1 | A Safety Study of SGN-CD19A for Leukemia and Lymphoma | February 2013 | May 30, 2017 |
| NCT01786135 | Completed | Phase 1 | A Safety Study of SGN-CD19A for B-Cell Lymphoma | February 2013 | February 16, 2017 |
| NCT01791595 | Completed | Phase 1 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | April 23, 2013 | November 17, 2020 |
| NCT03677128 | Completed | N/A | Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment | July 23, 2019 | April 22, 2022 |
| NCT00001337 | Completed | Phase 2 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | May 8, 1993 | May 24, 2024 |
| NCT00001237 | Completed | Phase 2 | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas | March 1989 | April 2000 |
| NCT01943682 | Completed | Phase 1 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | September 2013 | April 2019 |
| NCT04933617 | Completed | Phase 1 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | March 24, 2022 | November 30, 2023 |
| NCT04858568 | Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients | March 11, 2021 | January 31, 2024 | |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT00822432 | Completed | Coproporphyrine Isomers and Methotrexate Elimination | October 2007 | August 2011 | |
| NCT04488354 | Enrolling by invitation | Phase 1 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | January 21, 2021 | August 2036 |
| NCT06395103 | Not yet recruiting | Phase 1/Phase 2 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | June 4, 2024 | March 31, 2029 |
| NCT05990465 | Not yet recruiting | Phase 1 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | July 2024 | July 2027 |
| NCT05518383 | Recruiting | Phase 4 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | May 25, 2022 | May 16, 2027 |
| NCT05544019 | Recruiting | Phase 1 | Study of SGR-1505 in Mature B-Cell Neoplasms | April 10, 2023 | March 2026 |
| NCT05565417 | Recruiting | Phase 1/Phase 2 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | November 28, 2022 | April 2025 |
| NCT06131801 | Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | November 15, 2023 | December 1, 2027 | |
| NCT05794880 | Recruiting | N/A | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | May 1, 2023 | May 2032 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT06060782 | Recruiting | Phase 1 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine | October 1, 2023 | December 31, 2026 |
| NCT03223610 | Recruiting | Phase 1/Phase 2 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | February 9, 2018 | December 1, 2026 |
| NCT04195633 | Recruiting | Phase 2 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | January 25, 2021 | December 31, 2026 |
| NCT04425421 | Recruiting | Recommendations for the Treatment of Children With Burkitt's Lymphoma | November 1, 2020 | October 2026 | |
| NCT02393157 | Recruiting | Phase 2 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | August 21, 2015 | December 2024 |
| NCT03810196 | Recruiting | N/A | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | March 1, 2019 | January 2026 |
| NCT04491370 | Recruiting | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | August 1, 2021 | August 15, 2025 |
| NCT04545762 | Recruiting | Phase 1 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | September 11, 2020 | October 31, 2024 |
| NCT04739813 | Recruiting | Phase 1 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | July 9, 2021 | July 15, 2029 |
| NCT06340737 | Recruiting | Phase 1 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | March 29, 2024 | April 2031 |
| NCT03375619 | Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells | December 1, 2017 | January 1, 2035 | |
| NCT05020392 | Recruiting | Phase 3 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | September 14, 2021 | October 13, 2024 |
| NCT05263583 | Recruiting | Phase 2 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | December 9, 2022 | January 1, 2024 |
| NCT05270057 | Recruiting | Phase 1 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | January 26, 2023 | May 2026 |
| NCT05389423 | Recruiting | Phase 1 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | June 27, 2023 | June 1, 2032 |
| NCT00183976 | Terminated | Phase 2 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas | April 2005 | January 2006 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT02700022 | Terminated | Phase 1 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | October 2016 | August 18, 2017 |
| NCT03864419 | Terminated | Phase 1 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | October 24, 2019 | July 26, 2023 |
| NCT02483000 | Terminated | Phase 1 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | February 1, 2017 | September 2, 2020 |
| NCT01028716 | Terminated | Phase 2 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | May 19, 2010 | October 7, 2021 |
| NCT00180895 | Terminated | Phase 2 | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL | June 2004 | |
| NCT00126191 | Terminated | Phase 2 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | July 2005 | June 2011 |
| NCT00180882 | Unknown status | Phase 3 | LMBA02 Protocol for Patients With a Burkitt Lymphoma | October 2004 | |
| NCT03298828 | Unknown status | Phase 1 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | November 2017 | October 2022 |
| NCT02776891 | Withdrawn | Phase 2 | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma | June 13, 2016 | April 9, 2018 |
- Disase is a (Disease Ontology)
- DOID:706
- Cross Reference ID (Disease Ontology)
- GARD:5973
- Cross Reference ID (Disease Ontology)
- ICD10CM:C83.7
- Cross Reference ID (Disease Ontology)
- ICD9CM:200.2
- Cross Reference ID (Disease Ontology)
- ICDO:9687/3
- Cross Reference ID (Disease Ontology)
- MESH:D002051
- Cross Reference ID (Disease Ontology)
- MIM:113970
- Cross Reference ID (Disease Ontology)
- NCI:C2912
- Cross Reference ID (Disease Ontology)
- ORDO:543
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:118617000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0006413
- Exact Synonym (Disease Ontology)
- Burkitt lymphoma/leukaemia
- Exact Synonym (Disease Ontology)
- Burkitt's Lymphoma
- Exact Synonym (Disease Ontology)
- Burkitt's tumor
- Exact Synonym (Disease Ontology)
- Burkitt's tumor or lymphoma
- Exact Synonym (Disease Ontology)
- malignant lymphoma, Burkitt's type
- Exact Synonym (Disease Ontology)
- small Non-Cleaved cell Lymphoma, Burkitt's type
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030080
- OrphaNumber from OrphaNet (Orphanet)
- 543
- ICD10 preferred id (Insert disease from ICD10)
- D0002251
- ICD10 class code (Insert disease from ICD10)
- C83.7
- MeSH unique ID (MeSH (Medical Subject Headings))
- D002051